NASDAQ:PRVL Prevail Therapeutics Stock Forecast, Price & News Most-Downgraded Stocks Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Prevail Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.00 0.00 (0.00 %) (As of 01/22/2021) Add Compare Share Today's Range$23.00Now: $23.00▼$23.0050-Day Range$22.91MA: $23.01▼$23.2052-Week Range$9.02Now: $23.00▼$23.35VolumeN/AAverage Volume955,800 shsMarket Capitalization$787.66 millionP/E RatioN/ADividend YieldN/ABeta1.59 ProfileAnalyst RatingsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.Read More HeadlinesLilly Closes Acquisition Of Prevail TherapeuticsJanuary 22, 2021 | nasdaq.comSHAREHOLDER ALERT: Halper Sadeh LLP Investigates BPFH, SPWH, PRVL, SNCA; Shareholders Are Encouraged to Contact the FirmJanuary 13, 2021 | finance.yahoo.comSHAREHOLDER ALERT: WeissLaw LLP Reminds ANCN, PRVL, WORK, and GNBF Shareholders About Its Ongoing InvestigationsJanuary 6, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - MTSC, PRVL, ANH, CPAHDecember 28, 2020 | marketwatch.comLifshitz Law Firm, P.C. Announces Investigation of INFO, LORL, PS, and PRVLDecember 28, 2020 | finance.yahoo.comNotable Wednesday Option Activity: PRVL, IP, LBDecember 23, 2020 | nasdaq.comSHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies – PRVL, CATM, TCF, ZAGGDecember 22, 2020 | finance.yahoo.comHere's Why Lilly (LLY) Has Outperformed the Industry This YearDecember 21, 2020 | finance.yahoo.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Prevail Therapeutics, Inc. - PRVLDecember 18, 2020 | finance.yahoo.comLilly to Pick up PrevailDecember 15, 2020 | marketwatch.comSHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc.December 15, 2020 | finance.yahoo.comSHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Prevail Therapeutics Inc. (Nasdaq - PRVL)December 15, 2020 | finance.yahoo.comWhy Is It Moving? Analyzing The Upward Movement in Prevail Therapeutics's Stock TodayDecember 15, 2020 | benzinga.comEli Lilly to buy gene therapy developer Prevail in deal valued at $1.04 billionDecember 15, 2020 | reuters.comWhy Prevail Therapeutics Stock Is Skyrocketing TodayDecember 15, 2020 | fool.comPrevail Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Prevail Therapeutics Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PRVLDecember 15, 2020 | finance.yahoo.comPrevail Therapeutics, Oncocyte, Baidu: 5 Top Stock Gainers for TuesdayDecember 15, 2020 | finance.yahoo.comEli Lilly Acquiring Prevail Therapeutics in $880 Million DealDecember 15, 2020 | finance.yahoo.comEli Lilly to buy gene therapy developer Prevail in $1.04 bln dealDecember 15, 2020 | nasdaq.comWhat Eli Lilly Gets From Its Most Recent AcquisitionDecember 15, 2020 | 247wallst.comSee More Headlines Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRVL Previous Symbol CUSIPN/A CIKN/A Webwww.prevailtherapeutics.com Phone917-336-9310Employees66Year FoundedN/ADebt Debt-to-Equity RatioN/A Current Ratio7.56 Quick Ratio7.56 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book4.74Profitability EPS (Most Recent Fiscal Year)($2.22) Net Income$-63,190,000.00 Net MarginsN/A Return on Equity-55.57% Return on Assets-48.14% Miscellaneous Outstanding Shares34,246,000Market Cap$787.66 million Next Earnings Date3/25/2021 (Estimated) OptionableNot Optionable MarketRank™Overall MarketRank™1.34 out of 5 starsMedical Sector702nd out of 1,972 stocksBiological Products, Except Diagnostic Industry96th out of 177 stocksAnalyst Opinion: 2.1Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 - 2.1 Analyst's Opinion Consensus RatingPrevail Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.50, Prevail Therapeutics has a forecasted upside of 2.2% from its current price of $23.00.Amount of Analyst CoveragePrevail Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.1 Community Rank Outperform VotesPrevail Therapeutics has received 46 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPrevail Therapeutics has received 62 “underperform” votes. (Add your “underperform” vote.)Community SentimentPrevail Therapeutics has received 57.41% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Prevail Therapeutics and other stocks. Vote “Outperform” if you believe PRVL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRVL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPrevail Therapeutics does not currently pay a dividend.Dividend GrowthPrevail Therapeutics does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prevail Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders57.20% of the stock of Prevail Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.80% of the stock of Prevail Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prevail Therapeutics are expected to decrease in the coming year, from ($2.43) to ($2.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prevail Therapeutics is -10.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prevail Therapeutics is -10.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrevail Therapeutics has a P/B Ratio of 4.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Receive PRVL News and Ratings via Email Sign-up to receive the latest news and ratings for PRVL and its competitors with MarketBeat's FREE daily newsletter. Prevail Therapeutics (NASDAQ:PRVL) Frequently Asked Questions Is Prevail Therapeutics a buy right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prevail Therapeutics in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Prevail Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRVL, but not buy additional shares or sell existing shares. View analyst ratings for Prevail Therapeutics or view top-rated stocks. What stocks does MarketBeat like better than Prevail Therapeutics? Wall Street analysts have given Prevail Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Prevail Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. When is Prevail Therapeutics' next earnings date? Prevail Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021. View our earnings forecast for Prevail Therapeutics. How were Prevail Therapeutics' earnings last quarter? Prevail Therapeutics Inc. (NASDAQ:PRVL) posted its earnings results on Friday, November, 13th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.09. View Prevail Therapeutics' earnings history. What price target have analysts set for PRVL? 9 brokerages have issued 12 month price objectives for Prevail Therapeutics' stock. Their forecasts range from $20.00 to $26.00. On average, they expect Prevail Therapeutics' stock price to reach $23.50 in the next year. This suggests a possible upside of 2.2% from the stock's current price. View analysts' price targets for Prevail Therapeutics or view top-rated stocks among Wall Street analysts. Who are Prevail Therapeutics' key executives? Prevail Therapeutics' management team includes the following people: Dr. Asa Abeliovich M.D., Ph.D., Founder, Pres, CEO & Director (Age 56, Pay $737.47k)Dr. Yong Dai Ph.D., Chief Technology Officer (Age 49, Pay $450.62k)Dr. Jeffrey Sevigny M.D., Chief Medical Officer (Age 51, Pay $593k)Dr. Brett Kaplan M.D., CFO & Sec. (Age 46)Ms. Kira M. Schwartz, Gen. CounselMs. Emily Minkow, Chief Bus. Officer (Age 37)Dr. Franz F. Hefti Ph.D., Chief Devel. Officer (Age 72) Who are some of Prevail Therapeutics' key competitors? Some companies that are related to Prevail Therapeutics include Revolution Medicines (RVMD), NantKwest (NK), Editas Medicine (EDIT), NanoString Technologies (NSTG), Sorrento Therapeutics (SRNE), Kymera Therapeutics (KYMR), Bavarian Nordic A/S (BVNRY), AlloVir (ALVR), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), bluebird bio (BLUE), Scholar Rock (SRRK), C4 Therapeutics (CCCC), Translate Bio (TBIO) and Ocugen (OCGN). View all of PRVL's competitors. What other stocks do shareholders of Prevail Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prevail Therapeutics investors own include Sorrento Therapeutics (SRNE), Alector (ALEC), Gossamer Bio (GOSS), Editas Medicine (EDIT), Harpoon Therapeutics (HARP), Atreca (BCEL), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO) and Stoke Therapeutics (STOK). When did Prevail Therapeutics IPO? (PRVL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Prevail Therapeutics' stock symbol? Prevail Therapeutics trades on the NASDAQ under the ticker symbol "PRVL." Who are Prevail Therapeutics' major shareholders? Prevail Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.60%), Alpine Associates Management Inc. (2.50%), Alyeska Investment Group L.P. (1.74%), Alyeska Investment Group L.P. (1.74%), GABELLI & Co INVESTMENT ADVISERS INC. (0.60%) and Gabelli Funds LLC (0.53%). Company insiders that own Prevail Therapeutics stock include Acquisition Corp Tyto and Carl L Gordon. View institutional ownership trends for Prevail Therapeutics. Which major investors are selling Prevail Therapeutics stock? PRVL stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, JPMorgan Chase & Co., Squarepoint Ops LLC, Barclays PLC, Strs Ohio, GSA Capital Partners LLP, and Nuveen Asset Management LLC. View insider buying and selling activity for Prevail Therapeutics or view top insider-selling stocks. Which major investors are buying Prevail Therapeutics stock? PRVL stock was acquired by a variety of institutional investors in the last quarter, including Alpine Associates Management Inc., Alyeska Investment Group L.P., Alyeska Investment Group L.P., GABELLI & Co INVESTMENT ADVISERS INC., Gabelli Funds LLC, Glazer Capital LLC, Credit Suisse AG, and Water Island Capital LLC. Company insiders that have bought Prevail Therapeutics stock in the last two years include Acquisition Corp Tyto, and Carl L Gordon. View insider buying and selling activity for Prevail Therapeutics or or view top insider-buying stocks. What is Prevail Therapeutics' stock price today? One share of PRVL stock can currently be purchased for approximately $23.00. How much money does Prevail Therapeutics make? Prevail Therapeutics has a market capitalization of $787.66 million. The company earns $-63,190,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. How many employees does Prevail Therapeutics have? Prevail Therapeutics employs 66 workers across the globe. What is Prevail Therapeutics' official website? The official website for Prevail Therapeutics is www.prevailtherapeutics.com. Where are Prevail Therapeutics' headquarters? Prevail Therapeutics is headquartered at 430 East 29th Street Suite 1520, New York NY, 10016. How can I contact Prevail Therapeutics? Prevail Therapeutics' mailing address is 430 East 29th Street Suite 1520, New York NY, 10016. The company can be reached via phone at 917-336-9310 or via email at [email protected] This page was last updated on 3/6/2021 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here
